Skip to main content

Dravet Syndrome News

Related terms: Severe Myoclonic Epilepsy of Infancy, SMEI

Epilepsy in Children Linked to Lower QOL and Caregiver Strain

THURSDAY, Jan. 9, 2025 – Disability is a significant risk factor for lower quality of life (QOL) and increased caregiver burden among children with epilepsy and their caregivers, according to a...

Antiseizure Drug Diacomit Now Approved for Children as Young as 6 Months

SAN MATEO, Calif., Sept. 21, 2022 /PRNewswire/ – Biocodex, Inc., a pharmaceutical company and manufacturer of Diacomit® (stiripentol), announced today that the U.S. Food and Drug Administration (...

FDA Approves Fintepla (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome

EMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) – Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug...

FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome

On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved Diacomit (stiripentol) for seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. ...

FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome

On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved Diacomit (stiripentol) for seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. ...

FDA Approves Epidiolex (cannabidiol) to Treat Lennox-Gastaut Syndrome and Dravet Syndrome

June 25, 2018 – The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy,...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Epilepsy

Related drug support groups

cannabidiol